| 2008-09-22: |
Axxonis Pharma AG, has identified and patented several new chemical entities as neuroprotective agents
Berlin ( na Originaltextservice ) - The new compounds will provide a "full time" protection of neurons against aging and degeneration. Continuous administration technologies, which are one of the core competencies of Axxonis Pharma AG, will additionally enable the concept of 24 hours protection. (...) |
| 2008-09-22: |
Alzheimer's Disease International ( ADI )( 1 ) Launches Worldwide Campaign to Address Growing Public Health and Social Care Emergency
London ( PRN/ots ) - - Immediate Action Needed to Prepare for 100 Million Cases of Devastating Brain Disease Worldwide Expected by 2050( 2 ) A global call for action to address the growing public health and social care emergency posed by Alzheimer's disease and related dementias (...) |
| 2008-09-18: |
Agendia's MammaPrint( R ) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint( R ), has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare (...) |
| 2008-09-18: |
Enbrel( R ) Shown to Deliver Long - Lasting Improvements in Psoriasis Patients' Quality of Life
Maidenhead, England ( PRN/ots ) - - New Study Results Further Support That Enbrel Effectively Clears Skin, Reduces the Prevalence of Depression and Anxiety and Improves Patients' Quality of Life Data demonstrating the significant positive impact of Enbrel ( etanercept ) on the quality of life of (...) |
| 2008-09-16: |
SemBioSys Eligible to Proceed With Phase I/II Plant - Produced Insulin Trial After Submission of IND
Calgary, Canada ( PRN/ots ) - - TSX symbol: SBS SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it is eligible to proceed with its planned Phase I/II human clinical (...) |
| 2008-09-16: |
New Data Confirms Avastin ( R ) as the Only Biologic to Demonstrate Overall Survival When Used First - Line in Metastatic Colorectal Cancer Patients With K - RAS ( Wild - Type ) Gene Status
Basel, Switzerland ( PRN/ots ) - Avastin ( bevacizumab ) remains the only biologic to provide overall survival ( OS ) benefit when used as first - line treatment in combination with chemotherapy for patients with K - Ras wild type metastatic colorectal cancer ( mCRC ). Avastin's strong position was confirmed today following new (...) |
| 2008-09-15: |
South Africa Begins Introduction of PREVENAR into Childhood Immunization Program
Collegeville, Pennsylvania ( PRN/ots ) - - First African Nation Plans to Phase in Routine Vaccination Program Against Pneumococcal Disease for Infants and Young Children - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced that South Africa has initiated an immunization program against (...) |
| 2008-09-15: |
AVAiL Study Shows Longest Survival in Patients With Advanced Non - Small Cell Lung Cancer
Basel, Switzerland ( PRN/ots ) - - Final Analysis of Study Confirms Benefit of Avastin( R ) for Patients With Lung Cancer BASEL, Switzerland, September 15 /PRNewswire/ - - The final analysis of the Avastin in lung study ( AVAiL ) in patients with advanced lung cancer has shown that (...) |
| 2008-09-15: |
Pan - European Research Reveals Majority of Osteoporosis Patients not Receiving Recommended Combination of Calcium and Vitamin D With Treatment
Geneva ( PRN/ots ) - - Study Highlights Underlying Reasons for why Patients are Missing Their Supplementation GENEVA, September 15 /PRNewswire/ - - New research published today at the annual meeting of the American Society for Bone and Mineral Research ( ASBMR ), Montréal, Canada, reveals that less than (...) |
| 2008-09-15: |
Xeloda ( capecitabine ) Shown to be Superior to IV 5 - FU in Advanced Stomach and Oesophageal Cancer
Stockholm ( PRN/ots ) - - Patients Live Longer After Treatment With Capecitabine Chemotherapy Combinations Compared With Standard IV 5 - FU/FA - For Non - US and Non - UK Media Only Pooled results of two phase III trials have shown that stomach and oesophageal cancer (...) |
| 2008-09-11: |
Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs
Ingelheim, Germany ( PRN/ots ) - - For Non - US Healthcare Media - Global QUEST Study Reveals Dogs With Congestive Heart Failure Have Significantly Improved Survival Outcomes With Vetmedin( R ) ( pimobendan ) Veterinarians and dog owners are today welcoming new research that delivers the promise of an extended (...) |
| 2008-09-10: |
Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS( R ) and APIDRA( R ) Achieved Greater Reductions in A1C Than Those Treated With Pre - mixed Insulin
Paris ( PRN/ots ) - - Abstracts 186 and 1003 Sanofi - aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes ( EASD ) demonstrated that a basal - bolus insulin regimen (...) |
| 2008-09-10: |
Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS( R ) and APIDRA( R ) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
Paris ( PRN/ots ) - - Abstracts 185 and 1112 Sanofi - aventis, a world leader in diabetes care, announced results from two randomized clinical studies presented at the European Association for the Study of Diabetes ( EASD ) 44th Annual Meeting demonstrating that the "basal plus" insulin (...) |
| 2008-09-09: |
Fenofibrate Reduces the Risk of Amputations in Patients With Type 2 Diabetes
Rome ( PRN/ots ) - - Exciting New Data From the FIELD Study Show Additional Microvascular - Associated Benefits of Fenofibrate - The First Time in a Large - Scale Prospective Study That any Lipid - Modifying Therapy has Been Shown to Significantly Reduce the Risk of Lower - Limb (...) |
| 2008-09-08: |
Sanofi Aventis: New Real Life Studies Illustrate Greater A1C Lowering and Cost Benefit Observed With LANTUS( R ) Over Detemir and NPH Insulin
Paris ( PRN/ots ) - - The THIN, ROLE and LIVE - DE Studies Used Medical Databases or Medical Records to Compare the Benefits of Different Insulin Treatments in Thousands of People Living With Type 2 Diabetes - Abstracts 1000, 1001 and 1004 Sanofi - aventis, a (...) |
| 2008-09-04: |
Abbott Recognized on Dow Jones Sustainability Index ( DJSI ) for Fourth Consecutive Year
Abbott Park, Illinois ( PRN/ots ) - - Abbott Only U.S. - based Fortune 100 Health Care Manufacturer to Be Listed on Both North America and World Indexes Abbott ( NYSE: ABT ), the global health care company, announced today that it was recognized on the Dow (...) |
| 2008-09-03: |
Resverlogix Board of Directors Update
Calgary, Canada ( PRN/ots ) - - Provides Shareholders With an Update on Strategic Review Activities On behalf of Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) the Board of Directors, due to the recent advancement of various discussions with third parties, feel it is (...) |
| 2008-09-03: |
GNC Continues European Expansion Through Exclusive Online Distribution Agreement with Active Nutrition International for Sales of Sports Nutrition Products in Sweden, Finland, Denmark & Norway
Pittsburgh ( PRN/ots ) - General Nutrition Centers, Inc., the largest global specialty retailer of nutritional supplements, today announced another step in its continuing expansion in Europe through an exclusive distribution agreement for online sales of GNC's private label products, its first in Europe, in (...) |
| 2008-09-02: |
New Survey Among European Cardiologists Points to a Gap in Cardiovascular Disease Management
Munich, Germany ( PRN/ots ) - - In spite of the success of therapies targeting LDL in lowering cardiovascular risk, a residual risk still remains Cardiologists in Europe agree that reducing LDL - cholesterol ( LDL - C or "bad" cholesterol ) levels is the most important factor (...) |
| 2008-09-01: |
SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI
Washington ( PRN/ots ) - - At One Year, Angioplasty and Stenting Matches Bypass Surgery for Safety and Effectiveness in Patients with Complex Medical Condition Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings (...) |
| 2008-09-01: |
SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Washington ( PRN/ots ) - - One - Year Data Find Angioplasty and Stenting Safe and Effective in Patients for Whom Standard Therapy Has Been Open - Heart Surgery Data announced today from the landmark SYNTAX trial indicate that patients with very complex coronary artery disease (...) |
| 2008-09-01: |
Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study
Munich, Germany ( PRN/ots ) - Biosensors International Group, Ltd ( "Biosensors", "Company" ), ( Bloomberg: BIG:SP ), ( Singapore:B20 ) today announced that a next - generation drug - eluting stent, developed by Biosensors, has demonstrated equal safety and efficacy as compared to Johnson & Johnson's industry leading drug - eluting stent, (...) |
| 2008-09-01: |
American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone ( Multaq( R ) ) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
Montpellier, France ( PRN/ots ) - The ERATO study published today in the American Heart Journal demonstrated, for the first time in patients with permanent atrial fibrillation, that dronedarone ( Multaq( R ) ) significantly reduces mean 24 hour ventricular rate, on top of other rate control agents. The mean (...) |
| 2008-08-31: |
First Landmark ARB Trial Against Placebo Shows MICARDIS( R ) ( Telmisartan ) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE - Intolerant High - Risk Patients( 1 )
Munich, Germany ( PRN/ots ) - - TRANSCEND( R ), Parallel Trial to ONTARGET( R ), Confirms Long - Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg( 1 ) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ - - - For non - US Healthcare Media The results (...) |
| 2008-08-29: |
INTELENCE( TM ) ( Etravirine ) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Cork, Ireland ( PRN/ots ) - - INTELENCE is the First NNRTI to Show Antiviral Activity in Patients With NNRTI - Resistant Virus The European Medicines Agency ( EMEA ) has granted marketing authorisation for the anti - HIV medication INTELENCE( TM ) ( etravirine ). INTELENCE is a next generation non - nucleoside (...) |
| 2008-08-28: |
New Research Reveals That Mycamine( R ) is an Effective Treatment in Children, Young Babies and Premature Infants
Staines, England ( PRN/ots ) - - Not for distribution in the United Kingdom - Research Adds to Already Demonstrated Efficacy in Adult Population Parents and paediatricians are today welcoming the results of new research that adds additional support for an effective and well tolerated treatment (...) |
| 2008-08-26: |
After Their U.S. Purchase, Algorithme Pharma Gains a Foothold in Europe Through the Acquisition of a New Clinical Research Location in the United Kingdom
Laval, Canada ( PRN/ots ) - The Laval - based firm Algorithme Pharma is pleased to announce that it has achieved its goal of securing a European facility through its acquisition of Simbec Research Ltd in Merthyr Tydfil, Wales. This news comes only six weeks after confirming (...) |
| 2008-08-25: |
Phase 1b/2a Program Commences for RVX - 208
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX: RVX ) is pleased to announce that the Phase 1b/2a program for the study of RVX - 208 in subjects with normal lipids and those with low high - density lipoprotein ( HDL ) cholesterol has proceeded (...) |
| 2008-08-19: |
New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain
Indianapolis ( PRN/ots ) - - Study with duloxetine evaluating long - term pain reduction in treatment of DPNP is first to exceed three months Duloxetine hydrochloride maintained pain reduction in the treatment of diabetic peripheral neuropathic pain ( DPNP ) for more than six months,( 1 ) according to (...) |
| 2008-08-05: |
TMC278 Demonstrates Long - Term Efficacy and Tolerability in Treatment - Naïve Adults With HIV
Mexico City, Mexico ( PRN/ots ) - - Ninety - Six - Week Data on Tibotec Investigational NNRTI Presented at AIDS 2008 New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company's once - daily, investigational non - nucleoside reverse transcriptase inhibitor ( NNRTI ), provides long - term (...) |
| 2008-07-31: |
MabThera Filed in the EU for Treatment of Most Common Leukaemia in Adults
Basel, Switzerland ( PRN/ots ) - - Submission Based on Phase III Study Showing Superior Results for MabThera in Chronic Lymphocytic Leukaemia ( CLL ) When Added to Standard Chemotherapy Today, Roche submitted a Marketing Authorisation Application ( MAA ) to the European Medicines Agency ( EMEA ) for the use (...) |
| 2008-07-29: |
SemBioSys Submits IND for Safflower - Produced Insulin to U.S. FDA
Calgary ( PRN/ots ) - - Submission Demonstrates Progress of Plant - Derived Insulin Program Scheduled to Enter the Clinic Later This Year SemBioSys Genetics Inc. ( TSX:SBS ), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it (...) |
| 2008-07-28: |
Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System
Dar Es Salaam, Tanzania ( PRN/ots ) - - Partnership Will Modernize All Regional Hospital Laboratories to Improve Access to Care Across the Country At a ceremony today, the Ministry of Health and Social Welfare, United Republic of Tanzania, and Abbott Fund commemorated the (...) |
| 2008-07-24: |
Studies Assessed by European Health Authority Conclude That Impurity in Roche's Viracept( R ) ( nelfinavir mesylate ) Did Not Increase Patient's Risk of Cancer
Basel, Switzerland ( PRN/ots ) - The European Committee for Human Medicinal Products ( CHMP ) has confirmed that the presence of an impurity called ethyl methanesulfonate ( EMS ) in Roche's Viracept ( nelfinavir mesylate ) did not increase patients' risk of developing cancer. The discovery of the EMS impurity in (...) |
| 2008-07-21: |
Independent Analyses of the SEAS, SHARP and IMPROVE - IT Studies of Ezetimibe
London ( PRN/ots ) - The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit ( CTSU ) proposed that the hypothesis - generating results of the SEAS trial of ezetimibe should be tested by reviewing the combined cancer results from the SHARP and IMPROVE - IT trials (...) |
| 2008-07-21: |
Results From the SEAS ( Simvastatin and Ezetimibe in Aortic Stenosis ) Study
London ( PRN/ots ) - The SEAS ( Simvastatin and Ezetimibe in Aortic Stenosis ) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin ( 40 mg daily ) and ezetimibe ( 10 mg daily ) in patients with aortic stenosis. Aortic stenosis ( which involves partial blockage (...) |
| 2008-07-21: |
/C O R R E C T I O N - - Prof Terje Pedersen,SEAS Study Principal Investigator & Head of Steering Committee/
London ( PRN/ots ) - In the news release, "Update on the SEAS Study" issued on 21 Jul 2008 07:00 GMT, by Prof Terje Pedersen,SEAS Study Principal Investigator & Head of Steering Committee over PR Newswire, we are advised by a representative of the organisation (...) |
| 2008-07-21: |
Update on the SEAS Study
London ( PRN/ots ) - Professor Terje Pedersen ( Ullevål University Hospital, Oslo, Norway ), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis ( SEAS ) Study, will provide an update on the study on Monday the 21st July. Also present in London will be Sir Richard (...) |
| 2008-07-18: |
Resverlogix's Lead Drug Featured in Key Scientific Publication
Calgary, Canada ( PRN/ots ) - - RVX - 208 is the Only Apo - Al/HDL Drug to be Highlighted Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX:RVX ) is pleased to announce that Resverlogix's lead drug is featured prominently in an article titled "Emerging Antidyslipidemic (...) |
| 2008-07-16: |
Max Planck Society Awards Exclusive License to Dafra Pharma R&D to Develop a Drug Against Leishmaniasis
Turnhout, Belgium ( PRN/ots ) - Max Planck Innovation, the technology transfer agency of the Max Planck Society based in Munich, Germany and Dafra Pharma R&D, a Belgian research company belonging to Dafra Pharma International, today signed a license agreement for the development and commercialisation of (...) |
| 2008-07-09: |
Industry Leaders Select Resverlogix's RVX - 208 Among Top 10 Most Promising Drugs
Calgary, Canada ( PRN/ots ) - Resverlogix Corp's ( "Resverlogix" or the "Company" ) ( TSX:RVX ) novel lead ApoA - I drug candidate, RVX - 208 has been selected as one of the top 10 most promising cardiovascular disease ( CVD ) drugs available for strategic partnering by an independent committee assembled (...) |
| 2008-07-09: |
European Commission Announces Marketing Authorisation for 50mg Once Weekly Enbrel( R ) for Patients With Moderate - to - Severe Psoriasis
Maidenhead, England ( PRN/ots ) - - New Dosing Option Provides Greater Flexibility and Convenience for Patients to Effectively Control the Debilitating Symptoms of their Condition( 1 ) The European Commission announced today a new 50 mg Enbrel( R ) ( etanercept ) once weekly dosage regimen as an alternative to (...) |
| 2008-07-08: |
Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7 - Valent Pneumococcal Conjugate Vaccine ( PCV7 ) in Their Immunization Schedules
Maidenhead, England ( PRN/ots ) - - PREVENAR Vaccine to Help Protect Children Against the Leading Vaccine - Preventable Cause of Death in Young Children Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their (...) |
| 2008-07-07: |
European Medicines Agency ( EMEA ) Approves Relistor( TM ) The First - in - Class Treatment of Opioid - Induced Constipation ( OIC ) in Advanced - Illness Patients
Maidenhead, England ( PRN/ots ) - - First - in - Class Treatment set to Provide a New and Important Targeted Treatment for Distressing and near Universal Side Effect in Patients Receiving Opioids for Pain Relief as Part of Palliative Care Wyeth Pharmaceuticals, today 3rd July, (...) |
| 2008-07-07: |
Ferring Research Infertility and Gynaecology GrAnt ( FRIGGA ) 2008 Winners Announced
Barcelona ( PRN/ots ) - The winners of the Ferring Research Infertility and Gynaecology GrAnt ( FRIGGA ) are announced today at the European Society for Human Reproduction & Embryology Congress. The two winners of this new prize are the University Medical Centre Utrecht, The Netherlands and the (...) |
| 2008-07-03: |
Movetis' Second Most Advanced Product Progresses to Phase IIb Trial Following Positive Results in Cirrhotic Ascites
Turnhout, Belgium ( PRN/ots ) - Movetis NV, a European specialist pharmaceutical company, today announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple - dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients (...) |
| 2008-07-02: |
FDA Approves Abbott's XIENCE( TM ) V Drug Eluting Stent
Abbott Park, Illinois ( PRN/ots ) - - XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market - Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease Abbott today announced that the U.S. Food and Drug (...) |
| 2008-06-30: |
Honda to Conduct Collaborative Testing of its Walking Assist Device
Tokyo ( PRN/ots ) - Honda Motor Co., Ltd. will begin collaborative testing of its experimental walking assist device as from July 1, 2008, with Shinseikai Medical Group, Kasumigaseki - Minami Hospital ( Kawagoe, Saitama prefecture ). The device was created to support walking by the elderly and other (...) |
| 2008-06-27: |
INTELENCE( TM ) ( etravirine ) Receives Positive Opinion From European Committee for Human Medicinal Products ( CHMP ) for Treatment of HIV
Cork, Ireland ( PRN/ots ) - - INTELENCE is the first NNRTI to demonstrate antiviral activity in patients with NNRTI - resistant virus - Tibotec Pharmaceuticals, Ltd. announced today that the Committee for Human Medicinal Products ( CHMP ) of the European Medicines Agency ( EMEA ) has issued a (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
